Market Research Logo

Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2015

Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2015’, provides an overview of the Pancreatic Ductal Adenocarcinoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pancreatic Ductal Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Ductal Adenocarcinoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pancreatic Ductal Adenocarcinoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Pancreatic Ductal Adenocarcinoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Pancreatic Ductal Adenocarcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Pancreatic Ductal Adenocarcinoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Pancreatic Ductal Adenocarcinoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Pancreatic Ductal Adenocarcinoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Pancreatic Ductal Adenocarcinoma Overview
Therapeutics Development
Pipeline Products for Pancreatic Ductal Adenocarcinoma - Overview
Pipeline Products for Pancreatic Ductal Adenocarcinoma - Comparative Analysis
Pancreatic Ductal Adenocarcinoma - Therapeutics under Development by Companies
Pancreatic Ductal Adenocarcinoma - Therapeutics under Investigation by Universities/Institutes
Pancreatic Ductal Adenocarcinoma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Pancreatic Ductal Adenocarcinoma - Products under Development by Companies
Pancreatic Ductal Adenocarcinoma - Products under Investigation by Universities/Institutes
Pancreatic Ductal Adenocarcinoma - Companies Involved in Therapeutics Development
AbbVie Inc.
BerGenBio AS
Clovis Oncology, Inc.
Coare Biotechnology, Inc.
FibroGen, Inc.
Gilead Sciences, Inc.
Immodulon Therapeutics Ltd.
Immunomedics, Inc.
Incuron, LLC
Merck & Co., Inc.
Nerviano Medical Sciences S.r.l.
OncoMed Pharmaceuticals, Inc.
Sillajen Biotherapeutics
Tara Immuno-Oncology Therapeutics LLC
Tokai Pharmaceuticals, Inc.
Pancreatic Ductal Adenocarcinoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles BGB-324 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CBL-0137 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CBT-1111 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CBT-3112 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
demcizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FG-3019 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
galeterone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hu-5F9G4 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ibrutinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
idelalisib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IMM-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ipafricept - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JX-929 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-0752 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-8628 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
momelotinib dihydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MRK-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NMSP-715 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oligonucleotide to Inhibit IDO1 for Pancreatic Ductal Adenocarcinoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PSL-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rucaparib phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sacituzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SBP-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
siG12D-LODER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit Wnt Signal and eIF5A for Pancreatic Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Modulate GLT-1 for Pancreatic Ductal Adenocarcinoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vantictumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pancreatic Ductal Adenocarcinoma - Recent Pipeline Updates
Pancreatic Ductal Adenocarcinoma - Dormant Projects
Pancreatic Ductal Adenocarcinoma - Discontinued Products
Pancreatic Ductal Adenocarcinoma - Product Development Milestones
Featured News & Press Releases
Nov 09, 2015: Compelling Preclinical Data on Sun BioPharma's SBP-101 Presented at the 2015 American Pancreatic Association (APA) Annual Meeting
Oct 20, 2015: Sun BioPharma to Present Three Abstracts at the 2015 American Pancreatic Association Annual Meeting
Jun 25, 2013: Cleveland BioLabs And Incuron Announce Poster Presentation At ESMO 15th World Congress On Gastrointestinal Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Pancreatic Ductal Adenocarcinoma, H2 2015
Number of Products under Development for Pancreatic Ductal Adenocarcinoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Pancreatic Ductal Adenocarcinoma - Pipeline by AbbVie Inc., H2 2015
Pancreatic Ductal Adenocarcinoma - Pipeline by BerGenBio AS, H2 2015
Pancreatic Ductal Adenocarcinoma - Pipeline by Clovis Oncology, Inc., H2 2015
Pancreatic Ductal Adenocarcinoma - Pipeline by Coare Biotechnology, Inc., H2 2015
Pancreatic Ductal Adenocarcinoma - Pipeline by FibroGen, Inc., H2 2015
Pancreatic Ductal Adenocarcinoma - Pipeline by Gilead Sciences, Inc., H2 2015
Pancreatic Ductal Adenocarcinoma - Pipeline by Immodulon Therapeutics Ltd., H2 2015
Pancreatic Ductal Adenocarcinoma - Pipeline by Immunomedics, Inc., H2 2015
Pancreatic Ductal Adenocarcinoma - Pipeline by Incuron, LLC, H2 2015
Pancreatic Ductal Adenocarcinoma - Pipeline by Merck & Co., Inc., H2 2015
Pancreatic Ductal Adenocarcinoma - Pipeline by Nerviano Medical Sciences S.r.l., H2 2015
Pancreatic Ductal Adenocarcinoma - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2015
Pancreatic Ductal Adenocarcinoma - Pipeline by Sillajen Biotherapeutics, H2 2015
Pancreatic Ductal Adenocarcinoma - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2015
Pancreatic Ductal Adenocarcinoma - Pipeline by Tokai Pharmaceuticals, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Pancreatic Ductal Adenocarcinoma Therapeutics - Recent Pipeline Updates, H2 2015
Pancreatic Ductal Adenocarcinoma - Dormant Projects, H2 2015
Pancreatic Ductal Adenocarcinoma - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Pancreatic Ductal Adenocarcinoma, H2 2015
Number of Products under Development for Pancreatic Ductal Adenocarcinoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report